Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director | June 06, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,197 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 35,000 · Balance 100,197 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectShares held by The Malcolm and Cliona Brenner Revocable Trust | 163,732 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 163,732 F2: Shares held by The Malcolm and Cliona Brenner Revocable Trust, of which the Reporting Person is a trustee and settlor. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
F2: Shares held by The Malcolm and Cliona Brenner Revocable Trust, of which the Reporting Person is a trustee and settlor. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2024 Filed Jun 7, 2024 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070591 · ownership.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,197 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 11, 2023 Filed May 12, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029098 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,197 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:27 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-22-018833 · doc4.xml · derivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 25, 2021 Filed May 27, 2021 16:50 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0000899243-21-020866 · doc4.xml · derivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-24 F3 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 25, 2021 Filed May 27, 2021 16:50 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 818,663 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-020866 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 701 | $34.40 | $24,116.92 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 9 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 818,663 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.01 to $34.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,300 | $33.31 | $76,604.49 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 8 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 819,364 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.90 to $33.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 6,141 | $32.19 | $197,669.58 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 7 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 821,664 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.90 to $32.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,289 | $31.27 | $478,074.80 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 6 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 827,805 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.90 to $31.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 23,660 | $30.39 | $719,034.50 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 5 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 843,094 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,947 | $37.41 | $409,554.64 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 4 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 866,754 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.07 to $37.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,814 | $36.58 | $322,404.66 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 877,701 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.06 to $37.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 13,876 | $35.46 | $492,024.92 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 2 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 886,515 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.06 to $36.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,961 | $34.67 | $553,313.60 |
DisclosureSEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 900,391 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $35.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 03, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,500 | $38.53 | $327,471.85 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 8 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 916,352 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.30 to $38.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 03, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 6,032 | $37.73 | $227,616.92 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 7 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 924,852 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.29 to $38.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 03, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,383 | $36.91 | $124,861.12 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 6 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 930,884 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.29 to $37.285. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,614 | $39.14 | $63,172.77 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 5 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 934,267 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.89 to $39.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 7,317 | $38.27 | $280,016.47 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 4 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 935,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.87 to $38.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,727 | $37.35 | $139,198.98 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 943,198 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.845 to $37.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,869 | $39.00 | $345,899.87 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 2 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 946,925 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.61 to $39.585. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 20:34 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 12,825 | $38.39 | $492,327.38 |
DisclosureSEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 955,794 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.61 to $38.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 200 | $41.19 | $8,238.00 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 8 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 968,619 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.16 to $41.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,801 | $40.40 | $72,769.04 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 7 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 968,819 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.01 to $40.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,688 | $39.46 | $145,529.22 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 6 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 970,620 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.01 to $39.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,800 | $38.75 | $108,499.44 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 5 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 974,308 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.01 to $38.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 310 | $43.38 | $13,446.41 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 4 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 977,108 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.34 to $43.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,779 | $42.80 | $375,745.59 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 977,418 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.31 to $43.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,334 | $41.58 | $97,054.49 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 2 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 986,197 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.25 to $42.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 19:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,990 | $41.78 | $500,935.01 |
DisclosureSEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 988,531 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.31 to $42.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 08:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,982 | $41.49 | $123,731.83 |
DisclosureSEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,521 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.85 to $41.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 08:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,800 | $40.34 | $112,950.04 |
DisclosureSEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 2 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,003,503 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.85 to $40.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 08:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 975 | $39.68 | $38,683.91 |
DisclosureSEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,006,303 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.83 to $39.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 200 | $41.99 | $8,398.00 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 7 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,007,278 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,765 | $41.29 | $114,168.51 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 6 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,007,478 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.89 to $41.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,000 | $39.97 | $39,966.00 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 5 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,010,243 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.60 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,200 | $38.66 | $46,392.72 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 4 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,011,243 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 100 | $43.13 | $4,313.00 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,012,443 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,000 | $42.25 | $42,249.50 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 2 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,012,543 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.10 to $42.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,120 | $41.75 | $213,769.22 |
DisclosureSEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,013,543 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.10 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:55 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 1,518,018 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021586 · doc4.xml · derivative · entry 3 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,018,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:55 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionCommon Stock | 1,018,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021586 · doc4.xml · nonDerivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,018,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 18:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020913 · doc4.xml · derivative · entry 1 Brenner Malcolm · CIK 0001818068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-07-29 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.